JHS Svendgaard Laboratories Approves Modification to Preferential Issue Proceeds Utilization
JHS Svendgaard Laboratories Limited has approved a modification and clarification regarding the utilization of proceeds raised through its preferential issue, subject to shareholder approval. The Board of Directors confirmed the change, which is intended to provide greater flexibility in deploying funds towards capital expenditure, business expansion, strategic investments, and growth initiatives while achieving the original fundraising objectives.The Company’s board meeting addressed the variation in the use of the funds previously approved by shareholders via Postal Ballot on June 23, 2025. The original approval for raising funds through the preferential issue was granted at the Extra-Ordinary General Meeting held on July 04, 2024.
The modification clarifies and enhances the objectives of the capital infusion to support the evolving business requirements, manufacturing expansion plans, and long-term strategic goals of JHS Svendgaard Laboratories Limited.
Existing Planned Fund Utilization
Prior to the proposed amendment, the allocation of proceeds towards various corporate purposes was planned as follows:| Particulars | Total Estimated Amount (Rs Lakh) | Tentative Timelines for Utilization |
|---|---|---|
| Funding capital expenditure for acquiring manufacturing equipment | 599.99 | By December, 2026 |
| Infusion of funds in Group entities (JHS Svendgaard Retail Ventures Ltd.) | 1,650.00 | By December, 2026 |
| For General Corporate Purpose | 750.00 | By December, 2026 |
| Total | 2,999.99 |
Proposed Amended Utilization Objects
The proposed amendment reframes the utilization into three core objectives, with the total estimated amount remaining unchanged:| Particulars | Total Estimated Amount (Rs Lakh) | Tentative Timelines for Utilization |
|---|---|---|
| Capital Expenditure and Business Expansion | 1,174.99 | By March 31, 2027 |
| Strategic, Financial and Growth Initiatives | 1,075.00 | By March 31, 2027 |
| For General Corporate Purpose | 750.00 | By March 31, 2027 |
| Total | 2,999.99 |
The Board further specified the nature of these proposed objectives:
Capital Expenditure and Business Expansion involves funding and undertaking capital expenditure, infrastructure upgrades, resource sharing, manufacturing, and business development initiatives of the company.
Strategic, Financial and Growth Initiatives cover undertaking strategic investments, acquisitions, expansion initiatives, and restructuring activities to meet the growth objectives of the company. This includes direct or through investments in group companies, such as loans, advances, inter-corporate deposits, equity, or any other form of financial instruments, provided compliance with applicable laws is maintained.
The proposed modifications are primarily clarificatory in nature, intended to provide flexibility in fund deployment towards capital expenditure, business expansion, strategic investments, acquisitions, restructuring activities, and growth initiatives while preserving the original fundamental objectives for which the funds were raised.
JHS Stock Price Movement
Shares of JHS Svendgaard Laboratories Limited slipped by 0.26% on Thursday, concluding the trading session at ₹7.73. The stock traded within a range, hitting a day low of ₹7.70 and seeing a volume totaling 30,592 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: